Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신동해 | * |
dc.contributor.author | 김수원 | * |
dc.contributor.author | 김미선 | * |
dc.date.accessioned | 2022-07-13T16:30:02Z | - |
dc.date.available | 2022-07-13T16:30:02Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 1422-0067 | * |
dc.identifier.other | OAK-31707 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/261472 | - |
dc.description.abstract | The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wreaked havoc all over the world. Although vaccines for the disease have recently become available and started to be administered to the population in various countries, there is still a strong and urgent need for treatments to cure COVID-19. One of the safest and fastest strategies is represented by drug repurposing (DRPx). In this study, thirty compounds with known safety profiles were identified from a chemical library of Phase II-and-up compounds through a combination of SOM Biotech's Artificial Intelligence (AI) technology, (SOMPRO)-P-AI, and in silico docking calculations with third-party software. The selected compounds were then tested in vitro for inhibitory activity against SARS-CoV-2 main protease (3CLpro or Mpro). Of the thirty compounds, three (cynarine, eravacycline, and prexasertib) displayed strong inhibitory activity against SARS-CoV-2 3CLpro. VeroE6 cells infected with SARS-CoV-2 were used to find the cell protection capability of each candidate. Among the three compounds, only eravacycline showed potential antiviral activities with no significant cytotoxicity. A further study is planned for pre-clinical trials. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | SARS-CoV-2 3CL protease | * |
dc.subject | drug repurposing | * |
dc.subject | antiviral | * |
dc.subject | fret | * |
dc.subject | inhibitory compounds | * |
dc.title | A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors | * |
dc.type | Article | * |
dc.relation.issue | 12 | * |
dc.relation.volume | 23 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | * |
dc.identifier.doi | 10.3390/ijms23126468 | * |
dc.identifier.wosid | WOS:000816563600001 | * |
dc.identifier.scopusid | 2-s2.0-85131662559 | * |
dc.author.google | Jo, Seri | * |
dc.author.google | Signorile, Luca | * |
dc.author.google | Kim, Suwon | * |
dc.author.google | Kim, Mi-Sun | * |
dc.author.google | Huertas, Oscar | * |
dc.author.google | Insa, Raul | * |
dc.author.google | Reig, Nuria | * |
dc.author.google | Shin, Dong Hae | * |
dc.contributor.scopusid | 신동해(57217374185) | * |
dc.contributor.scopusid | 김수원(57193241841) | * |
dc.contributor.scopusid | 김미선(57203466599;57195150819) | * |
dc.date.modifydate | 20240429141437 | * |